Amplia Therapeutics Limited INNMF
0.06 USD 0.00 (+0.00%)
At closeNov 10, 2026, 4:00 PM EST
0.0575 Day range 0.0575
0.05 52-week range 0.27
- YTD
- -26.58%
- 1 year
- -30.95%
News
proactiveinvestors.com Amplia Therapeutics partners with Lilly on lung cancer combination trial Amplia Therapeutics Ltd (ASX:ATX, OTCQB:INNMF) has signed a clinical collaboration agreement with Eli Lilly and Company to evaluate its lead drug...
globenewswire.com Amplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly's Kras G12C Inhibitor, Olomorasib, in Non-small Cell Lung Cancer HIGHLIGHTS Amplia has executed a Clinical Trial Collaboration & Supply Agreement (CTCSA) with Eli Lilly & Company, to evaluate the Company's investigational FAK inhibitor narmafotinib in combination…
globenewswire.com Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online HIGHLIGHTS A manuscript describing comprehensive preclinical studies of narmafotinib in models of pancreatic cancer is now available online. The findings provide further evidence of narmafotinib's…
globenewswire.com Amplia Announces Publication of New FAK Inhibitor Patent Application HIGHLIGHTS New patent application published covering chemically novel FAK inhibitors discovered by Amplia Application expands Amplia's intellectual property portfolio supporting its FAK inhibitor…
globenewswire.com Amplia Announces Appointment of Brett Carter to Board Melbourne, Australia, July 07, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX, OTCQB:INNMF), (“Amplia” or the “Company”), is pleased to announce the appointment of Mr Brett Carter to…
globenewswire.com Amplia Announces Changes to Board's Leadership Roles Melbourne, Australia, July 06, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX, OTCQB:INNMF), (“Amplia” or the “Company”), announces Board changes further to a Board renewal and…
globenewswire.com Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer Melbourne, Australia, June 22, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX | OTCQB:INNMF), (“Amplia” or the “Company”) provides a letter to shareholders from CEO and Managing…
globenewswire.com Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib HIGHLIGHTS New Phase 2b study builds on compelling Phase 1b/2a ACCENT study data to lay foundation for Phase 3 registrational study Focus on investigating new, daily dosing of narmafotinib in…
globenewswire.com Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study Melbourne, Australia, May 08, 2026 (GLOBE NEWSWIRE) -- HIGHLIGHTS Amplia and ANZGOG enter into agreement to conduct a clinical study in ovarian cancer evaluating narmafotinib in combination with…
globenewswire.com Accent Trial Mature Data Presented at International Conference HIGHLIGHTS Mature data from Amplia's ACCENT trial in pancreatic cancer is being presented at the prestigious American Association of Cancer Research (AACR) annual meeting The ACCENT trial…
proactiveinvestors.com Altona Rare Earths shares jump 11% as gallium results exceed expectations at Mozambique project Altona Rare Earths, the London-listed critical materials explorer, saw its shares rise 11% to 3.11 pence on Tuesday after reporting that gallium...
proactiveinvestors.com Amplia flags key ACCENT milestone as 5 complete responses sharpen narmafotinib case in pancreatic cancer Amplia Therapeutics Ltd (ASX:ATX, OTCQB:INNMF)'s ACCENT trial has reached an important milestone after an independent central review confirmed five complete...
proactiveinvestors.com X‑Energy files to go public on the Nasdaq, eyes $300M raise US nuclear technology developer X‑Energy has filed paperwork with the Securities and Exchange Commission to launch an initial public offering on Nasdaq,...
globenewswire.com Amplia Therapeutics to Present at the Life Sciences Investor Forum on March 12th The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at…
globenewswire.com Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models HIGHLIGHTS Amplia's lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US conference Data showing narmafotinib activity in preclinical…
globenewswire.com Amplia Therapeutics Announces Opening of US Sites for Amplicity Pancreatic Cancer Trial Melbourne, Australia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- HIGHLIGHTS Two US-based sites have completed trial initiation activities for the AMPLICITY trial in pancreatic cancer These sites join the two…
globenewswire.com Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025 Melbourne, Australia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Key Highlights from the Quarter ACCENT Trial Success: The ACCENT trial, testing narmafotinib with gemcitabine and Abraxane®, continues to…
globenewswire.com ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM HIGHLIGHTS Results from the Phase 2a ACCENT trial in pancreatic cancer have been presented at the specialist conference ASCO Gastrointestinal Cancer Symposium Updated data analysis continues to show…
globenewswire.com Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium Melbourne, Australia, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF) (“Amplia” or the “Company”) is pleased to announce that the Company's CMO Dr Jason Lickliter…
globenewswire.com Additional Confirmed Response Reported as Part of Amplia Investor Presentation HIGHLIGHTS An additional confirmed partial response has been recorded in the ongoing ACCENT trial This brings the confirmed Objective Response Rate to 35% Updated data to be presented at the Life…